 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gregory Berkin, Chief Information Officer of Lisata, to participate in keynote discussion on CISO leadership and managing the risks of artificial intelligenceBASKING RIDGE, N.J., Sept. 20, 2023...

Lisata Therapeutics Announces Participation in InfoSec World 2023

Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standards of care versus standards of care alone in subjects with advanced solid tumors...

Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Lisata Therapeutics says IDSMC recommends study continuation of ASCEND trial

Independent Data Safety Monitoring Committee recommends study continuation (criteria for futility not met)BASKING RIDGE, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq...

Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma

BASKING RIDGE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ( Lisata or the Company ), a clinical-stage pharmaceutical company developing innovative therapies...

Lisata Therapeutics Announces Participation in Upcoming Conferences in September

Lisata Therapeutics, Inc. (NASDAQ:LSTA Free Report) Investment analysts at Brookline Capital Management cut their Q3 2023 earnings estimates for shares of Lisata Therapeutics in a report issued on Tuesday, August 15th. Brookline Capital Management analyst K. Dolliver now expects that the company ...

Brookline Capital Management Analysts Cut Earnings Estimates for Lisata Therapeutics, Inc. (NASDAQ:LSTA)

Lisata Therapeutics, Inc. (NASDAQ:LSTA Free Report) Analysts at HC Wainwright lifted their Q3 2023 earnings estimates for shares of Lisata Therapeutics in a research note issued on Tuesday, August 15th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of...

Lisata Therapeutics, Inc. Expected to Post Q3 2023 Earnings of ($0.92) Per Share (NASDAQ:LSTA)

HC Wainwright restated their buy rating on shares of Lisata Therapeutics (NASDAQ:LSTA  Free Report) in a research report report published on Tuesday, Benzinga reports. They currently have a...

Lisata Therapeutics (NASDAQ:LSTA) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Lisata Therapeutics (NASDAQ:LSTA Free Report) in a research report report published on Tuesday, Benzinga reports. They currently have a $15.00 target price on the stock. HC Wainwright also issued estimates for Lisata Therapeutics Q3 2023 earnings ...

Lisata Therapeutics, Inc. (LSTA) Q2 2023 Earnings Call Transcript

Lisata Therapeutics, Inc. develops biopharmaceuticals. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. The company is headquartered in Basking Ridge, NJ.

Watchers	9,385
52-Wk Low	$1.95
52-Wk High	$5.16

Market Cap	$17.02M
Volume (M)	10,658.00
52-Wk High	$5.16
52-Wk Low	$1.95

LSTA Lisata Therapeutics Inc

About

Feed

News

Earnings

Fundamentals